A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

E. Edwards, John; M. Schwartz, Michael; S. Schmidt, Clint; D. Sobel, Jack; Nyirjesy, Paul; Schödel, F.; Marchus, Erica; Lizakowski, Mary; A DeMontigny, Elizabeth; Hoeg, Jesse; Holmberg, Tuomas; Timothy Cooke, M.; Hoover, Keila; Edwards, Lance; Jacobs, Mark; A. Sussman, Steven; Augenbraun, Michael; F. Drusano, Michael; R. Yeaman, Michael; S. Ibrahim, Ashraf; G. Filler, Scott; P. Hennessey, John

doi:10.1093/cid/ciy185

Public

A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

Published in Clinical Infectious Diseases • Mar 1, 2018

Authors:

John E. Edwards

Michael M. Schwartz

Clint S. Schmidt

Abstract

Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomize...

Subject

Medicine

Double blind

Vulvovaginal Candidiasis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!